Payment overview · 2025
General Payments
$341.05
15 reported records · 10 companies
Healthcare provider profile · identity verified
Vidyamohan Balu
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JACINTO, CA · NPI 1265815880
Verified facts
What the public records show
CMS Open Payments records show Vidyamohan Balu received $341.05 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.47 | 28.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.16 | 15.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.43 | 14.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.00 | 7.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.11 | 7.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.92 | 7.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.48 | 6.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.84 | 4.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.52 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.12 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.05 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.43 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.11 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 235 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
348 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
235 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 953 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 857 | 213 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 536 | 107 |
| Gabapentin | Gabapentin | 459 | 108 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 457 | 67 |
| Metformin Hcl | Metformin Hcl | 440 | 97 |
| Furosemide | Furosemide | 400 | 104 |
| Lisinopril | Lisinopril | 359 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 102 |
| Jardiance | Empagliflozin | 348 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 78 |
| Omeprazole | Omeprazole | 321 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 65 |
| Losartan Potassium | Losartan Potassium | 293 | 79 |
| Alprazolam | Alprazolam | 274 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 72 |
| Baclofen | Baclofen | 268 | 54 |
| Glipizide | Glipizide | 250 | 54 |
| Ozempic | Semaglutide | 235 | 33 |
| Ibuprofen | Ibuprofen | 232 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 42 |
| Trazodone Hcl | Trazodone Hcl | 205 | 60 |
| Lorazepam | Lorazepam | 201 | 36 |
| Montelukast Sodium | Montelukast Sodium | 181 | 38 |
| Promethazine Hcl | Promethazine Hcl | 180 | 69 |
| Pregabalin | Pregabalin | 179 | 35 |
| Potassium Chloride | Potassium Chloride | 169 | 47 |
| Morphine Sulfate Er | Morphine Sulfate | 168 | 21 |
| Tramadol Hcl | Tramadol Hcl | 160 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 44 |
| Eliquis | Apixaban | 151 | 30 |
| Carvedilol | Carvedilol | 150 | 45 |
| Meloxicam | Meloxicam | 149 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 148 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 38 |
| Azithromycin | Azithromycin | 130 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 34 |
| Benazepril Hcl | Benazepril Hcl | 121 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 120 | 30 |
| Methylprednisolone | Methylprednisolone | 119 | 87 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 26 |
| Lidocaine | Lidocaine | 111 | 23 |
| Clonidine Hcl | Clonidine Hcl | 110 | 31 |
| Nitroglycerin | Nitroglycerin | 107 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 26 |
| Ondansetron Odt | Ondansetron | 102 | 34 |
| Famotidine | Famotidine | 94 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 41 |
| Lactulose | Lactulose | 90 | 23 |
| Cephalexin | Cephalexin | 87 | 51 |
| Diazepam | Diazepam | 87 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 78 | 13 |
| Simvastatin | Simvastatin | 78 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 20 |
| Labetalol Hcl | Labetalol Hcl | 76 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 51 |
| Myrbetriq | Mirabegron | 72 | 14 |
| Atenolol | Atenolol | 71 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 68 | 12 |
| Propranolol Hcl | Propranolol Hcl | 68 | suppressed |
| Temazepam | Temazepam | 66 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 17 |
| Mirtazapine | Mirtazapine | 63 | 17 |
| Meclizine Hcl | Meclizine Hcl | 62 | 17 |
| Prednisone | Prednisone | 61 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Allopurinol | Allopurinol | 58 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 15 |
| Sertraline Hcl | Sertraline Hcl | 58 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 32 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Januvia | Sitagliptin Phosphate | 53 | 11 |
| Alendronate Sodium | Alendronate Sodium | 52 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 11 |
| Spironolactone | Spironolactone | 49 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Amoxicillin | Amoxicillin | 48 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | 13 |
| Methocarbamol | Methocarbamol | 47 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 16 |
| Rybelsus | Semaglutide | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 15 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Ubrelvy | Ubrogepant | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 20 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 35 | 19 |
| Fluconazole | Fluconazole | 35 | 21 |
| Linzess | Linaclotide | 35 | suppressed |
| Nystatin | Nystatin | 35 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 22 |
| Levofloxacin | Levofloxacin | 32 | 21 |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 22 |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 13 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 22 | suppressed |
| Terbutaline Sulfate | Terbutaline Sulfate | 22 | suppressed |
| Ztlido | Lidocaine | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 20 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.05 · 15 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, CAPLYTA, DUPIXENT, FREESTYLE LIBRE 3, IBSRELA, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error